Actinium Pharmaceuticals (ATNM) Net Equity Issued and Repurchased (2014 - 2024)

Actinium Pharmaceuticals (ATNM) has reported Net Equity Issued and Repurchased for 11 consecutive years, with -$645000.0 the latest figure, recorded in Q4 2024.

• In Q4 2024, Net Equity Issued and Repurchased fell 154.07% year-over-year to -$645000.0; the TTM figure through Dec 2024 stood at $29.3 million (up 100.21% YoY), while the FY2024 annual figure was $29.3 million, up 100.21% from the prior year.
• Net Equity Issued and Repurchased fell to -$645000.0 in Q4 2024 per ATNM's latest filing, from $5.2 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $200.0 million in Q3 2020 and bottomed at -$645000.0 in Q4 2024.
• Historically, Net Equity Issued and Repurchased has averaged $21.3 million across 5 years, with a median of $5.2 million in 2024.
• On a YoY basis, Net Equity Issued and Repurchased climbed as much as 1808.44% in 2024 and fell as far as 154.07% in 2024.
• Actinium Pharmaceuticals' Net Equity Issued and Repurchased stood at $22.6 million in 2020, then tumbled by 101.33% to -$300000.0 in 2021, then jumped by 1731.33% to $4.9 million in 2022, then slumped by 75.62% to $1.2 million in 2023, then plunged by 154.07% to -$645000.0 in 2024.
• Business Quant data shows ATNM's Net Equity Issued and Repurchased at -$645000.0 in Q4 2024, $5.2 million in Q3 2024, and $10.0 million in Q2 2024.